Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05774704 · ClinicalTrials.gov registry record · Phase 1
Curcumin and Retinal Study
A Phase 1 study of Gut Microbiome and Safety, sponsored by Texas Tech University Health Sciences Center.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 60
- Enrollment target
- 1
- Study location
NCT05774704: Recruiting Phase 1 study of Gut Microbiome and Safety, sponsored by Texas Tech University Health Sciences Center.
NCT05774704 is a Phase 1 study of Gut Microbiome and Safety that is actively recruiting participants, run by Texas Tech University Health Sciences Center. The registered enrollment target is 60 participants, below the 265-participant average among 22 other Gut Microbiome trials with a reported enrollment target (77% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05774704, a Phase 1 study of Gut Microbiome and Safety, is actively recruiting participants, sponsored by Texas Tech University Health Sciences Center.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 60 participants
- Enrollment target
- 1
- Study location
Study Summary
To test how two weeks of curcumin supplementation would cross the blood brain barrier (BBB) and attach to amyloid beta proteins, to assess the feasibility (safety and bioavailability), and to explore the resulting abundance/composition of gut microbiota.
Primary Outcome
To access amyloid fluorescent intensity
Conditions Studied
Interventions
- DRUG Low curcumin group
- DRUG High curcumin group
Study Locations (1)
Texas
- Texas Tech University Health Sciences Center - Lubbock
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 60 participants |
| Start Date | 2023-08-21 |
| Est. Completion | 2026-12-31 |
| Phase | Phase 1 |
What NCT05774704 shows while recruiting
NCT05774704 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 60 participants, a relatively small participant target, below the 265-participant average among 22 other Gut Microbiome trials with a reported enrollment target (77% lower).
The record links to 3 conditions, with Gut Microbiome appearing as the primary indexed condition, and to 2 interventions - of which Low curcumin group is the first listed.
NCT05774704 reports a single indexed study location in Texas.
Frequently Asked Questions
What is clinical trial NCT05774704 about?
NCT05774704 is a clinical study titled "Curcumin and Retinal Study". To test how two weeks of curcumin supplementation would cross the blood brain barrier (BBB) and attach to amyloid beta proteins, to assess the feasibility (safety and bioavailability), and to explore the resulting abundance/composition of gut microbiota.
What is the current status of trial NCT05774704?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 60 participants. The study started on 2023-08-21. Estimated completion is 2026-12-31.
What conditions does trial NCT05774704 study?
This clinical trial studies the following conditions: Gut Microbiome, Safety, Bioavailability.
What interventions are being tested in trial NCT05774704?
The interventions under investigation include: Low curcumin group (DRUG), High curcumin group (DRUG).
Who is sponsoring clinical trial NCT05774704?
This trial is sponsored by Texas Tech University Health Sciences Center, which has 76 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05774704 being conducted?
This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Gut Microbiome
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05774704's enrollment target sits among peer trials
60 10th of 22 higher than 11 of 22 other Gut Microbiome trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Gut Microbiome trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Flourish: Exploring the Early Infant Gut Microbiome
RECRUITING · NA
-
The Path Study: Cognitive and Inflammation Targeted Gut-brain Interventions in Alcohol; Probiotics, Alcohol, Transcutaneous Vagus Nerve Stimulation, and HIV Study
RECRUITING · NA
-
Enhanced Nutritional Optimization in LVAD Trial
RECRUITING · NA
-
Feasibility and Potential Efficacy of Herbs and Spices for Improving Dietary Quality in College Students: A Pilot Study
RECRUITING · NA
-
How a Single Workout Affects Gut Bugs in Women With Different Fitness Levels and Body Types
RECRUITING · NA
-
Gut Microbiome and Treatment for Gynecological Cancer Patients Receiving Immunotherapy
RECRUITING
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00576069 · 60 participants
Mechanism(s)of Airflow Limitation in Moderate-severe Persistent Asthma
- NCT01297400 · 60 participants · Phase 2
Phase 2 Pilot Study of the Safety and Efficacy of Topical MW-III in Thermal Burns
- NCT01734122 · 60 participants
Stereotactic Radiosurgery for Essential Tremor and Parkinsonian Tremor
- NCT01804634 · 60 participants · Phase 2
Reduced Intensity Haploidentical BMT for High Risk Solid Tumors
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI